S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Bausch Health Companies (BHC) Stock Forecast, Price & News

+0.01 (+0.10%)
(As of 05/27/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
4.97 million shs
Average Volume
5.61 million shs
Market Capitalization
$3.56 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BHC News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter.

Bausch Health Companies logo

About Bausch Health Companies

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Sales & Book Value

Annual Sales
$8.43 billion
Cash Flow
$8.66 per share
Book Value
($0.39) per share


Net Income
$-948 million
Pretax Margin




Free Float
Market Cap
$3.56 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.70 out of 5 stars

Medical Sector

56th out of 1,427 stocks

Pharmaceutical Preparations Industry

19th out of 683 stocks

Analyst Opinion: 3.4Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 2.5 5 -4 -3 -2 -1 -

Bausch Health Companies (NYSE:BHC) Frequently Asked Questions

Is Bausch Health Companies a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bausch Health Companies stock.
View analyst ratings for Bausch Health Companies
or view top-rated stocks.

Are investors shorting Bausch Health Companies?

Bausch Health Companies saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 18,090,000 shares, an increase of 24.2% from the April 30th total of 14,570,000 shares. Based on an average daily volume of 6,280,000 shares, the days-to-cover ratio is presently 2.9 days. Approximately 5.2% of the shares of the company are short sold.
View Bausch Health Companies' Short Interest

When is Bausch Health Companies' next earnings date?

Bausch Health Companies is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Bausch Health Companies

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc. (NYSE:BHC) released its quarterly earnings data on Tuesday, May, 10th. The company reported $0.72 EPS for the quarter, missing analysts' consensus estimates of $1.03 by $0.31. The business had revenue of $1.92 billion for the quarter, compared to the consensus estimate of $2.06 billion. Bausch Health Companies had a negative trailing twelve-month return on equity of 649.29% and a negative net margin of 4.89%.
View Bausch Health Companies' earnings history

What guidance has Bausch Health Companies issued on next quarter's earnings?

Bausch Health Companies updated its FY 2022 earnings guidance on Tuesday, May, 24th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $8.25 billion-$8.40 billion.

What price target have analysts set for BHC?

5 equities research analysts have issued 1 year price targets for Bausch Health Companies' shares. Their forecasts range from $7.00 to $31.00. On average, they expect Bausch Health Companies' stock price to reach $16.40 in the next twelve months. This suggests a possible upside of 66.2% from the stock's current price.
View analysts' price targets for Bausch Health Companies
or view top-rated stocks among Wall Street analysts.

Who are Bausch Health Companies' key executives?
Bausch Health Companies' management team includes the following people:
  • Mr. Joseph C. Papa, Chairman & CEO (Age 66, Pay $3.74M)
  • Ms. Christina M. Ackermann, Exec. VP, Gen. Counsel & Head of Commercial Operations (Age 57, Pay $1.31M)
  • Mr. Paul S. Herendeen, Exec. VP and Advisor to Chairman & CEO (Age 66, Pay $2.1M)
  • Mr. Thomas J. Appio, Pres & Co-Head Bausch + Lomb/International (Age 60, Pay $2.16M)
  • Mr. Osama A. Eldessouky, CFO & Exec. VP (Age 50) (LinkedIn Profile)
  • Mr. Frederick J. Munsch, Sr. VP, Controller & Chief Accounting Officer (Age 51)
  • Dr. Robert F. Butz, VP of Medical & Scientific Affairs
  • Mr. Arthur J. Shannon, Sr. VP and Head of Investor Relations & Global Communications
  • Ms. Kelly Webber, Sr. VP & Chief HR Officer
  • Mr. Dennis Asharin, Sr. VP and Chief Global Manufacturing & Supply Chain Officer
What is Joseph C. Papa's approval rating as Bausch Health Companies' CEO?

43 employees have rated Bausch Health Companies CEO Joseph C. Papa on Glassdoor.com. Joseph C. Papa has an approval rating of 97% among Bausch Health Companies' employees. This puts Joseph C. Papa in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Gilead Sciences (GILD), Micron Technology (MU), Constellation Software (CSU), Intact Financial (IFC), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Advanced Micro Devices (AMD) and Bank of America (BAC).

What is Bausch Health Companies' stock symbol?

Bausch Health Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHC."

Who are Bausch Health Companies' major shareholders?

Bausch Health Companies' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.83%), Glenview Capital Management LLC (2.56%), Guardian Capital LP (1.08%), Permian Investment Partners LP (0.97%), Bank of Montreal Can (0.89%) and Fiera Capital Corp (0.85%). Company insiders that own Bausch Health Companies stock include Amy B Wechsler, Christina Ackermann, Holdings LP Valueact, Joseph F Gordon, Robert Spurr, Russell Barrans, Sam Eldessouky, Schutter Richard U De, Steven D Miller and William D Humphries.
View institutional ownership trends for Bausch Health Companies

Which institutional investors are selling Bausch Health Companies stock?

BHC stock was sold by a variety of institutional investors in the last quarter, including Glenview Capital Management LLC, Permian Investment Partners LP, Group One Trading L.P., Goldman Sachs Group Inc., Canyon Capital Advisors LLC, Verition Fund Management LLC, M.D. Sass Investors Services Inc., and Cibc World Market Inc.. Company insiders that have sold Bausch Health Companies company stock in the last year include Christina Ackermann, Joseph F Gordon, Robert Spurr, and Sam Eldessouky.
View insider buying and selling activity for Bausch Health Companies
or view top insider-selling stocks.

Which institutional investors are buying Bausch Health Companies stock?

BHC stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, National Bank of Canada FI, Arrowstreet Capital Limited Partnership, Ghisallo Capital Management LLC, Steigerwald Gordon & Koch Inc., Vanguard Group Inc., Gamco Investors INC. ET AL, and Gamco Investors INC. ET AL. Company insiders that have bought Bausch Health Companies stock in the last two years include Holdings LP Valueact, Russell Barrans, Schutter Richard U De, and Steven D Miller.
View insider buying and selling activity for Bausch Health Companies
or or view top insider-buying stocks.

How do I buy shares of Bausch Health Companies?

Shares of BHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bausch Health Companies' stock price today?

One share of BHC stock can currently be purchased for approximately $9.87.

How much money does Bausch Health Companies make?

Bausch Health Companies has a market capitalization of $3.56 billion and generates $8.43 billion in revenue each year. The company earns $-948 million in net income (profit) each year or ($1.14) on an earnings per share basis.

How many employees does Bausch Health Companies have?

Bausch Health Companies employs 19,600 workers across the globe.

What is Bausch Health Companies' official website?

The official website for Bausch Health Companies is www.bauschhealth.com.

How can I contact Bausch Health Companies?

Bausch Health Companies' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The company can be reached via phone at (514) 744-6792, via email at [email protected], or via fax at 514-744-6272.

This page was last updated on 5/29/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.